IL279530B2 - Benzodiazepine history, preparations, and methods for treating cognitive disorder - Google Patents
Benzodiazepine history, preparations, and methods for treating cognitive disorderInfo
- Publication number
- IL279530B2 IL279530B2 IL279530A IL27953020A IL279530B2 IL 279530 B2 IL279530 B2 IL 279530B2 IL 279530 A IL279530 A IL 279530A IL 27953020 A IL27953020 A IL 27953020A IL 279530 B2 IL279530 B2 IL 279530B2
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- aryl
- membered heteroaryl
- aliphatic
- isomer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862687195P | 2018-06-19 | 2018-06-19 | |
| PCT/US2019/038038 WO2019246300A1 (en) | 2018-06-19 | 2019-06-19 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL279530A IL279530A (en) | 2021-01-31 |
| IL279530B1 IL279530B1 (en) | 2025-09-01 |
| IL279530B2 true IL279530B2 (en) | 2026-01-01 |
Family
ID=68984202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL279530A IL279530B2 (en) | 2018-06-19 | 2019-06-19 | Benzodiazepine history, preparations, and methods for treating cognitive disorder |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11414425B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3810611A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7514534B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112601749B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019288382B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020026062B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3104478A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202190076A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL279530B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020013927A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019246300A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4032889B1 (en) | 2013-12-20 | 2026-05-06 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| EP3310785B1 (en) | 2015-06-19 | 2024-11-20 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| AU2019288382B2 (en) | 2018-06-19 | 2024-07-25 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| IL294031A (en) * | 2019-12-19 | 2022-08-01 | Agenebio Inc | History of benzodiazepines, preparations and methods for the treatment of cognitive impairment |
| EP4178961A4 (en) * | 2020-07-10 | 2024-07-31 | Agenebio, Inc. | POLYMORPHS OF A GABAA APLHA5 AGONIST AND METHODS OF USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT |
| JP7867287B2 (ja) * | 2020-07-10 | 2026-05-29 | エージンバイオ, インコーポレイテッド | Gabaaアルファ5アゴニストおよびsv2a阻害剤の組合せ物ならびに認知障害の処置において使用する方法 |
| WO2024023268A1 (en) | 2022-07-29 | 2024-02-01 | F. Hoffmann-La Roche Ag | Characterisation of neurological dysfunction |
| EP4572852A1 (en) | 2022-08-19 | 2025-06-25 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
| JPWO2024162378A1 (cg-RX-API-DMAC7.html) * | 2023-02-01 | 2024-08-08 | ||
| CN117756848A (zh) * | 2023-11-30 | 2024-03-26 | 常州大学 | 一种th-302衍生物及其制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002040487A2 (en) * | 2000-11-16 | 2002-05-23 | F. Hoffmann-La Roche Ag | Benzodiazepine derivatives as gaba a receptor modulators |
| WO2015095783A1 (en) * | 2013-12-20 | 2015-06-25 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| WO2016205739A1 (en) * | 2015-06-19 | 2016-12-22 | Belew Mekonnen | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| WO2018130868A1 (en) * | 2016-12-19 | 2018-07-19 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| NL7305644A (cg-RX-API-DMAC7.html) | 1972-04-20 | 1973-10-23 | ||
| NL7605526A (nl) | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
| JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4816456A (en) | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
| NL195004C (nl) | 1987-03-04 | 2003-11-04 | Novartis Ag | Fenylcarbamaat bevattend farmaceutisch preparaat. |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| CA2000786C (en) | 1988-11-07 | 1999-01-26 | Janssen Pharmaceutica, Naamloze Vennootschap | 3-piperidinyl-1,2-benzisoxazoles |
| US5043345A (en) | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| DE10299048I2 (de) | 1989-04-14 | 2006-07-13 | Merz Pharma Gmbh & Co Kgaa | Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie |
| ES2076253T3 (es) | 1989-05-19 | 1995-11-01 | Hoechst Roussel Pharma | N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos. |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| ATE180475T1 (de) | 1990-09-21 | 1999-06-15 | Rohm & Haas | Dihydropyridazinone und pyridazinone als fungizide |
| US5190951A (en) | 1990-10-19 | 1993-03-02 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| WO1992020682A1 (en) | 1991-05-24 | 1992-11-26 | E.I. Du Pont De Nemours And Company | Arthropodicidal anilides |
| US5106856A (en) | 1991-06-07 | 1992-04-21 | Hoechst-Roussel Pharmaceuticals Inc. | [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds |
| TW201311B (cg-RX-API-DMAC7.html) | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| ATE167057T1 (de) | 1994-03-02 | 1998-06-15 | Akzo Nobel Nv | Sublinguales oder bukkales arzneimittel |
| US6479523B1 (en) | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
| WO1999025353A1 (en) | 1997-11-13 | 1999-05-27 | Merck Sharp & Dohme Limited | Therapeutic uses of triazolo-pyridazine derivatives |
| US6294583B1 (en) | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| CA2349700A1 (en) | 1998-11-12 | 2000-05-18 | Merck & Co., Inc. | Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same |
| US6677330B1 (en) | 1999-03-03 | 2004-01-13 | Eisai Co., Ltd. | Fluorides of 4-substituted piperidine derivatives |
| GB9911803D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911804D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911802D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9929569D0 (en) | 1999-12-14 | 2000-02-09 | Merck Sharp & Dohme | Therapeutic agents |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US20020151591A1 (en) | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| IL157465A0 (en) | 2001-03-01 | 2004-03-28 | Pfizer Products Inc Pfizer Pro | Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders |
| US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| WO2003025122A2 (en) | 2001-08-13 | 2003-03-27 | University Of Kentucky Research Foundation | Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment |
| CA2473536A1 (en) | 2002-01-16 | 2003-07-31 | Endo Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating disorders of the central nervous system |
| CA2495285A1 (en) | 2002-08-13 | 2004-02-19 | Merck Sharp & Dohme Limited | Phenylpyridazine derivatives as ligands for gaba receptors |
| GB0218876D0 (en) | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| US7635709B2 (en) | 2002-09-26 | 2009-12-22 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction |
| CN100339070C (zh) | 2002-10-24 | 2007-09-26 | 莫茨药物股份两合公司 | 包含1-氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物 |
| MXPA05005398A (es) | 2002-11-22 | 2006-03-09 | Univ Johns Hopkins | Meta para terapia de deterioro cognitivo. |
| AU2004316119B2 (en) | 2003-10-22 | 2008-04-24 | Merz Pharma Gmbh & Co. Kgaa | The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic AB peptides in amyloidopathies |
| US20060079582A1 (en) | 2004-09-23 | 2006-04-13 | Jeffrey Jonas | Memantine for the treatment of childhood behavioral disorders |
| ATE402707T1 (de) | 2004-10-12 | 2008-08-15 | Hoffmann La Roche | Imidazoä1,5aütriazoloä1,5dübenzodiazepin- derivative zur behandlung kognitiver störungen |
| NZ554439A (en) | 2004-10-20 | 2009-09-25 | Hoffmann La Roche | Imidazo-benzodiazepine derivatives |
| RU2007114763A (ru) | 2004-10-20 | 2008-11-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Галогенозамещенные производные бензодиазепинов |
| WO2006063708A1 (en) | 2004-12-14 | 2006-06-22 | F.Hoffmann-La Roche Ag | Tetracyclic imidazo-benzodiazepines as gaba receptors modulators |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| US7595395B2 (en) | 2005-05-16 | 2009-09-29 | Wisys Technology Foundation | Gabaergic agents to treat memory deficits |
| EP1924712B1 (en) | 2005-08-03 | 2018-10-03 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| US8510055B2 (en) | 2005-08-03 | 2013-08-13 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| JP4885967B2 (ja) | 2005-10-11 | 2012-02-29 | エフ.ホフマン−ラ ロシュ アーゲー | イミダゾベンゾジアゼピン誘導体 |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| WO2010014220A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
| WO2010036553A1 (en) | 2008-09-24 | 2010-04-01 | E. I. Du Pont De Nemours And Company | Fungicidal pyridazines |
| BRPI0920515B1 (pt) | 2008-09-25 | 2018-03-20 | Vive Nano, Inc. | Composição compreendendo nanopartícula de polímero e composto ativo agrícola |
| EP2419401A2 (en) | 2009-04-17 | 2012-02-22 | XenoPort, Inc. | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAb RECEPTOR LIGANDS |
| WO2011085406A1 (en) | 2010-01-11 | 2011-07-14 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| CN103189062B (zh) | 2010-11-05 | 2016-03-23 | 霍夫曼-拉罗奇有限公司 | 活性药物化合物用于治疗中枢神经系统病症的用途 |
| AU2011328993B2 (en) | 2010-11-15 | 2017-03-02 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
| MX2013005443A (es) | 2010-11-15 | 2013-10-07 | Agenebio Inc | Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo. |
| JPWO2012161133A1 (ja) | 2011-05-20 | 2014-07-31 | 日産化学工業株式会社 | 置換ピリダジン化合物及び農園芸用殺菌剤 |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| WO2014039920A1 (en) | 2012-09-10 | 2014-03-13 | Lewin Matthew R | Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade |
| CN108567786A (zh) * | 2017-03-10 | 2018-09-25 | 陈洪国 | 一种治疗溃疡性结肠炎的药物组合物 |
| CN108567787A (zh) * | 2017-03-10 | 2018-09-25 | 辛衍雪 | 一种治疗慢性阻塞性肺病的药物组合物 |
| AU2019288382B2 (en) | 2018-06-19 | 2024-07-25 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
-
2019
- 2019-06-19 AU AU2019288382A patent/AU2019288382B2/en active Active
- 2019-06-19 MX MX2020013927A patent/MX2020013927A/es unknown
- 2019-06-19 CN CN201980053122.8A patent/CN112601749B/zh active Active
- 2019-06-19 EA EA202190076A patent/EA202190076A1/ru unknown
- 2019-06-19 CA CA3104478A patent/CA3104478A1/en active Pending
- 2019-06-19 EP EP19822528.6A patent/EP3810611A4/en active Pending
- 2019-06-19 JP JP2020571354A patent/JP7514534B2/ja active Active
- 2019-06-19 WO PCT/US2019/038038 patent/WO2019246300A1/en not_active Ceased
- 2019-06-19 BR BR112020026062-2A patent/BR112020026062B1/pt not_active IP Right Cessation
- 2019-06-19 US US16/445,854 patent/US11414425B2/en active Active
- 2019-06-19 IL IL279530A patent/IL279530B2/en unknown
-
2022
- 2022-06-27 US US17/850,144 patent/US12291535B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002040487A2 (en) * | 2000-11-16 | 2002-05-23 | F. Hoffmann-La Roche Ag | Benzodiazepine derivatives as gaba a receptor modulators |
| WO2015095783A1 (en) * | 2013-12-20 | 2015-06-25 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| WO2016205739A1 (en) * | 2015-06-19 | 2016-12-22 | Belew Mekonnen | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| WO2018130868A1 (en) * | 2016-12-19 | 2018-07-19 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
Also Published As
| Publication number | Publication date |
|---|---|
| IL279530B1 (en) | 2025-09-01 |
| US20200048268A1 (en) | 2020-02-13 |
| EA202190076A1 (ru) | 2021-09-22 |
| AU2019288382A1 (en) | 2021-02-11 |
| BR112020026062B1 (pt) | 2023-04-04 |
| US11414425B2 (en) | 2022-08-16 |
| CN112601749A (zh) | 2021-04-02 |
| AU2019288382B2 (en) | 2024-07-25 |
| JP7514534B2 (ja) | 2024-07-11 |
| IL279530A (en) | 2021-01-31 |
| US20230107032A1 (en) | 2023-04-06 |
| CN112601749B (zh) | 2024-03-26 |
| EP3810611A1 (en) | 2021-04-28 |
| JP2021528427A (ja) | 2021-10-21 |
| US12291535B2 (en) | 2025-05-06 |
| WO2019246300A1 (en) | 2019-12-26 |
| MX2020013927A (es) | 2021-03-02 |
| NZ772066A (en) | 2025-05-30 |
| BR112020026062A2 (pt) | 2021-03-23 |
| CA3104478A1 (en) | 2019-12-26 |
| EP3810611A4 (en) | 2022-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12291535B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| US12528819B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| IL278053B2 (en) | Peptide macrocycles against acinetobacter baumannii | |
| AU2014368961B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| IL256354B (en) | Benzodiazepine derivatives, compositions, and uses thereof for treating cognitive impairment | |
| IL294031A (en) | History of benzodiazepines, preparations and methods for the treatment of cognitive impairment | |
| HK40077472A (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| OA20303A (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment. | |
| AU2023324882A1 (en) | Benzazepine derivatives, compositions, and methods for treating cognitive impairment | |
| HK40016046B (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| HK40016046A (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| OA19667A (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment. | |
| HK1230170A1 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| HK1230170B (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |